Japan has historically been a favorable geography for medical device launches. But increasingly frequent and significant price cuts and the detrimental effects of international reference pricing have put this traditional practice in jeopardy. Representatives of the medtech industry consulted with Japan’s Ministry of Health, Labour and Welfare (MHLW) regarding its vision for how the pricing and reimbursement system should evolve in Japan.

The client asked L.E.K. Consulting to help develop its position on what the future of pricing and reimbursement for medical devices should look like in Japan.

L.E.K.’s approach

L.E.K. conducted individual workshops with the client’s medtech business units and aggregated the findings to produce a high-level summary of the company’s vision for the healthcare industry in Japan; the challenges to reaching this vision; the role that the medtech industry can play in Japan to help achieve the vision; and the required government policy changes.

Value delivered to the client

L.E.K. developed a policy paper that the client can provide to external stakeholders (e.g., industry associations or MHLW) to explain why proposed policy changes are necessary and important (see Figure 1). 

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2024 L.E.K. Consulting LLC 

Late Lifecycle Strategy Assessment for a Biologic
people reviewing data
See how we enabled a global pharmaceutical company to optimize the late life cycle opportunity for its biologic asset by developing a globally coherent pricing and access strategy.

Related Insights